US8153602B1
(en)
*
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
GB9514435D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Danisco |
Inhibition of gene expression
|
US7074768B2
(en)
|
1995-08-17 |
2006-07-11 |
Idera Pharmaceuticals, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US6624293B1
(en)
|
1995-08-17 |
2003-09-23 |
Hybridon, Inc. |
Modified protein kinase A-specific oligonucleotides and methods of their use
|
US5652356A
(en)
*
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
GB9519299D0
(en)
|
1995-09-21 |
1995-11-22 |
Farrar Gwyneth J |
Genetic strategy
|
GB9604449D0
(en)
*
|
1996-03-01 |
1996-05-01 |
Farrar Gwyneth J |
Genetic strategy ii
|
US8551970B2
(en)
|
1996-04-02 |
2013-10-08 |
Optigen Patents Limited |
Genetic suppression and replacement
|
GB9606961D0
(en)
|
1996-04-02 |
1996-06-05 |
Farrar Gwyneth J |
Genetic strategy III
|
US20030036519A1
(en)
*
|
1998-04-21 |
2003-02-20 |
Ryszard Kole |
Stable alteration of pre-mrna splicing patterns by modified rnas
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
JP2004509604A
(ja)
*
|
2000-03-28 |
2004-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
mRNAプロセッシングのアンチセンスモジュレーションによる、細胞行動の改変
|
KR20020097241A
(ko)
*
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
EP1191097A1
(en)
*
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
GB2382577A
(en)
*
|
2001-11-28 |
2003-06-04 |
Talat Nasim |
A reporter-based assay for assessing relative RNA processing activity in mammaliian cells
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
ES2414091T3
(es)
|
2003-07-17 |
2013-07-18 |
Unilever N.V. |
Procedimiento de estabilización de una dispersión comestible que comprende aceite
|
WO2005072527A2
(en)
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
WO2005094370A2
(en)
*
|
2004-03-29 |
2005-10-13 |
The General Hospital Corporation |
Oligonucleotide complex compositions and methods of use as gene alteration tools
|
PL2206781T3
(pl)
*
|
2004-06-28 |
2016-06-30 |
Univ Western Australia |
Antysensowne oligonukleotydy do indukowania pomijania eksonów i sposoby ich zastosowania
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
WO2006087093A1
(en)
|
2005-02-17 |
2006-08-24 |
Unilever N.V. |
Process for the preparation of a spreadable dispersion comprising sterol
|
AU2006242371A1
(en)
*
|
2005-04-29 |
2006-11-09 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for regulated expression of nucleic acid at post-transcriptional level
|
EP1910395B1
(en)
|
2005-06-23 |
2012-10-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of SMN2 splicing
|
EP1937312B1
(en)
|
2005-08-30 |
2016-06-29 |
Ionis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
US8258109B2
(en)
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
US7785834B2
(en)
*
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
AU2006315758A1
(en)
*
|
2005-11-10 |
2007-05-24 |
Ercole Biotech, Inc. |
Splice switching oligomers for TNF superfamily receptors and their use in treatment of disease
|
EP1976567B1
(en)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
AU2007282224B2
(en)
|
2006-08-11 |
2013-08-29 |
Vico Therapeutics B.V. |
Methods and means for treating DNA repeat instability associated genetic disorders
|
US20090264353A1
(en)
*
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
AU2008262391A1
(en)
|
2007-06-06 |
2008-12-18 |
Avi Biopharma, Inc. |
Soluble HER2 and HER3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
|
EP2167135A2
(en)
*
|
2007-07-12 |
2010-03-31 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
WO2009054725A2
(en)
|
2007-10-26 |
2009-04-30 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
EP2219680A2
(en)
|
2007-11-13 |
2010-08-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
CN105779453A
(zh)
|
2008-10-24 |
2016-07-20 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
CN102317458B
(zh)
|
2008-12-04 |
2018-01-02 |
库尔纳公司 |
通过红细胞生成素(epo)天然反义转录物的抑制对epo相关疾病的治疗
|
WO2010065671A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
RU2746478C2
(ru)
|
2008-12-04 |
2021-04-14 |
КьюРНА, Инк. |
Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
|
US20120021515A1
(en)
|
2009-02-06 |
2012-01-26 |
Swayze Eric E |
Oligomeric compounds and methods
|
PT2396038E
(pt)
|
2009-02-12 |
2016-02-19 |
Curna Inc |
Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
|
ES2656290T3
(es)
|
2009-03-16 |
2018-02-26 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor nuclear (derivado de eritroide 2) similar al 2 (NRF2) mediante inhibición del transcrito antisentido natural a NRF2
|
EP2408920B1
(en)
|
2009-03-17 |
2017-03-08 |
CuRNA, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
JP2012524540A
(ja)
|
2009-04-24 |
2012-10-18 |
プロセンサ テクノロジーズ ビー.ブイ. |
Dmdを処置するためのイノシンを含むオリゴヌクレオチド
|
KR101722541B1
(ko)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Ttp에 대한 천연 안티센스 전사체의 억제에 의한 트리스테트라프롤린 관련된 질환의 치료
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
US9012139B2
(en)
|
2009-05-08 |
2015-04-21 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
EP2432882B1
(en)
|
2009-05-22 |
2019-12-25 |
CuRNA, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
EP2443237B1
(en)
|
2009-06-16 |
2017-02-22 |
CuRNA, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
WO2010148249A1
(en)
|
2009-06-17 |
2010-12-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing in a subject
|
CN102597238B
(zh)
|
2009-06-24 |
2016-06-29 |
库尔纳公司 |
通过抑制针对肿瘤坏死因子受体2(tnfr2)的天然反义转录物来治疗tnfr2相关的疾病
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
CA2768947C
(en)
|
2009-07-24 |
2018-06-19 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
KR101827015B1
(ko)
|
2009-08-11 |
2018-02-07 |
큐알엔에이, 인크. |
아디포넥틴(adipoq)에 대한 천연 안티센스 전사체의 억제에 의한 아디포넥틴(adipoq) 관련된 질환의 치료
|
EP2982755B1
(en)
|
2009-08-21 |
2020-10-07 |
CuRNA, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療
|
WO2011038210A2
(en)
|
2009-09-25 |
2011-03-31 |
Curna, Inc. |
Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
|
EE05711B1
(et)
*
|
2009-10-07 |
2014-04-15 |
Tartu Ülikool |
Meetod ja kompositsioon konditsionaalselt letaalsete viirusmutantide loomiseks ja eukarootse raku elulisuse k?rvaldamiseks
|
NZ626359A
(en)
|
2009-11-12 |
2016-02-26 |
Univ Western Australia |
Antisense molecules and methods for treating pathologies
|
KR101823702B1
(ko)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
막 결합 전사 인자 펩티다제, 부위 1(mbtps1)에 대한 천연 안티센스 전사체의 억제에 의한 mbtps1 관련 질환의 치료
|
JP6031356B2
(ja)
|
2009-12-23 |
2016-11-24 |
カッパーアールエヌエー,インコーポレイテッド |
Ucp2に対する天然アンチセンス転写産物の阻害による脱共役タンパク質2(ucp2)関連疾患の治療
|
US8940708B2
(en)
|
2009-12-23 |
2015-01-27 |
Curna, Inc. |
Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
|
ES2616561T3
(es)
|
2009-12-24 |
2017-06-13 |
Biomarin Technologies B.V. |
Molécula para tratar un trastorno inflamatorio
|
CN102782134B
(zh)
|
2009-12-29 |
2017-11-24 |
库尔纳公司 |
通过抑制核呼吸因子1(nrf1)的天然反义转录物而治疗nrf1相关疾病
|
CA2785177C
(en)
|
2009-12-29 |
2019-09-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
JP6083735B2
(ja)
|
2009-12-31 |
2017-02-22 |
カッパーアールエヌエー,インコーポレイテッド |
インスリン受容体基質2(irs2)および転写因子3(tfe3)に対する天然アンチセンス転写物の阻害によるインスリン受容体基質2(irs2)関連疾患の治療
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
WO2011085066A2
(en)
|
2010-01-06 |
2011-07-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
EP2524039B1
(en)
|
2010-01-11 |
2017-11-29 |
CuRNA, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
RU2611192C2
(ru)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С РНКазой Н1, ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К РНКазе Н1
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
CN102971423B
(zh)
|
2010-05-26 |
2018-01-26 |
库尔纳公司 |
通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病
|
CA2802616C
(en)
|
2010-06-22 |
2018-07-10 |
Unilever Plc |
Edible fat powders
|
PT2585596T
(pt)
|
2010-06-23 |
2021-03-23 |
Curna Inc |
Tratamento de doenças relacionadas com a subunidade alfa de canais de sódio dependentes de voltagem (scna) por inibição da transcrição antissentido natural para scna
|
US8980860B2
(en)
|
2010-07-14 |
2015-03-17 |
Curna, Inc. |
Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
|
CN103210086B
(zh)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
|
EP2630241B1
(en)
|
2010-10-22 |
2018-10-17 |
CuRNA, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
EP2638163B1
(en)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
WO2012068340A2
(en)
|
2010-11-18 |
2012-05-24 |
Opko Curna Llc |
Antagonat compositions and methods of use
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US20130266715A1
(en)
|
2010-12-17 |
2013-10-10 |
René Joachim Buter |
Process of compacting a microporous fat powder and compacted fat powder so obtained
|
WO2012079957A1
(en)
|
2010-12-17 |
2012-06-21 |
Unilever Nv |
Edible water in oil emulsion
|
US20140221607A1
(en)
|
2011-06-08 |
2014-08-07 |
Indiana University Research And Technology Corp. |
Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
|
CA2838588C
(en)
|
2011-06-09 |
2021-09-14 |
Curna, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
MX365525B
(es)
|
2011-09-06 |
2019-06-06 |
Curna Inc |
Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
US20150025231A1
(en)
|
2012-01-11 |
2015-01-22 |
Cold Spring Harbor Laboratory |
Compositions and methods for modulation of ikbkap splicing
|
WO2013112053A1
(en)
|
2012-01-27 |
2013-08-01 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
KR20140136488A
(ko)
|
2012-03-15 |
2014-11-28 |
큐알엔에이, 인크. |
뇌 유래 신경영양 인자(bdnf)에 대한 천연 안티센스 전사체의 저해에 의한 뇌 유래 신경영양 인자(bdnf)관련 질환의 치료
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
CN104583402A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节mecp2表达的组合物和方法
|
AU2013287353B2
(en)
|
2012-07-12 |
2018-11-08 |
Proqr Therapeutics Ii B.V. |
Oligonucleotides for making a change in the sequence of a target RNA molecule present in a living cell
|
BR112015014987A2
(pt)
|
2012-12-20 |
2017-08-15 |
Sarepta Therapeutics Inc |
Aprimoradas composições que pulam éxon para o tratamento da distrofia muscular
|
US9926559B2
(en)
|
2013-01-09 |
2018-03-27 |
Biogen Ma Inc. |
Compositions and methods for modulation of SMN2 splicing in a subject
|
KR20230074606A
(ko)
|
2013-03-14 |
2023-05-30 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이영양증의 치료를 위한 엑손 스키핑 조성물
|
EP3998339A1
(en)
|
2013-03-14 |
2022-05-18 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
EP3662912A1
(en)
|
2013-03-15 |
2020-06-10 |
Sarepta Therapeutics, Inc. |
Improved dosages of eteplirsen for treating duchenne muscular dystrophy
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
EP3052632A4
(en)
|
2013-10-04 |
2017-03-29 |
Rana Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
MA39835A
(fr)
|
2014-04-17 |
2017-02-22 |
Biogen Ma Inc |
Compositions et procédés de modulation de l'épissage du smn2 chez un patient
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
WO2016054615A2
(en)
|
2014-10-03 |
2016-04-07 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
EP3212824A4
(en)
|
2014-10-30 |
2018-08-08 |
The General Hospital Corporation |
Methods for modulating atrx-dependent gene repression
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
WO2017060731A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
US11136584B2
(en)
|
2015-11-04 |
2021-10-05 |
Duke University |
Splice-switching oligonucleotides and methods of use
|
LT3386511T
(lt)
|
2015-12-10 |
2021-08-25 |
Ptc Therapeutics, Inc. |
Hantingtono ligos gydymo būdai
|
EP3390636B1
(en)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
US10920225B2
(en)
*
|
2016-05-03 |
2021-02-16 |
Taichung Veterans General Hospital |
Antisense oligonucleotide for splicing adjustment of mutant dopa decarboxylase gene and using method thereof
|
US11198867B2
(en)
|
2016-06-16 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Combinations for the modulation of SMN expression
|
CA3025575A1
(en)
|
2016-06-30 |
2018-01-04 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
EP4122497B1
(en)
|
2016-12-19 |
2024-04-10 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
CA3047010A1
(en)
|
2016-12-19 |
2018-06-28 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
LT3554553T
(lt)
|
2016-12-19 |
2022-08-25 |
Sarepta Therapeutics, Inc. |
Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos
|
MX2019014514A
(es)
|
2017-06-05 |
2020-07-20 |
Ptc Therapeutics Inc |
Compuestos para tratar la enfermedad de huntington.
|
CA3067591A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
Methods for treating huntington's disease
|
EP3645121A4
(en)
|
2017-06-28 |
2021-03-17 |
PTC Therapeutics, Inc. |
HUNTINGTON'S DISEASE TREATMENT METHODS
|
CA3073515A1
(en)
|
2017-08-25 |
2019-02-28 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of conditions and diseases
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
WO2019190927A2
(en)
|
2018-03-26 |
2019-10-03 |
Duke University |
Splice-switching oligonucleotides and methods of use
|
EA202092001A1
(ru)
|
2018-03-27 |
2021-01-29 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения болезни гентингтона
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
US11858941B2
(en)
|
2018-06-27 |
2024-01-02 |
Ptc Therapeutics, Inc. |
Heterocyclic and heteroaryl compounds for treating Huntington's disease
|
EP3942049A4
(en)
|
2019-03-20 |
2023-10-18 |
President And Fellows Of Harvard College |
PROGRANULIN AUGMENTATION THERAPY BASED ON ANTI-SENSE OLIGONUCLEOTIDES IN NEURODEGENERATIVE DISEASES
|
JP2022528725A
(ja)
|
2019-04-18 |
2022-06-15 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを治療するための組成物
|
CN112111528B
(zh)
*
|
2019-06-21 |
2024-04-02 |
华东师范大学 |
一种内含子异常剪接的修复方法
|
CA3156848A1
(en)
|
2019-11-01 |
2021-05-06 |
Novartis Ag |
The use of a splicing modulator for a treatment slowing progression of huntington's disease
|
KR20220148230A
(ko)
|
2020-02-28 |
2022-11-04 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Smn2를 조절하기 위한 화합물 및 방법
|
US20230287410A1
(en)
|
2020-05-11 |
2023-09-14 |
Stoke Therapeutics, Inc. |
Opa1 antisense oligomers for treatment of conditions and diseases
|
TW202304446A
(zh)
|
2021-03-29 |
2023-02-01 |
瑞士商諾華公司 |
剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|